COVID-19 Vaccine Antibodies Decline Rapidly In Dialysis Patients

  • New research suggests that antibody responses to immunization against SARS-CoV-2, the coronavirus that causes COVID-19, diminish fast in dialysis patients, raising the likelihood of breakthrough infection.

The findings come from a prospective case-control study including 4791 patients from throughout the country. Researchers looked at the link between vaccine-induced antibodies to SARS-receptor-binding CoV-2’s domain (RBD) and the development of breakthrough infection. They compared each breakthrough case to five patients (controls) based on age, gender, and vaccination month, as well as diabetes status and location.

Shuchi Anand, MD, of Stanford University in Palo Alto, California, and colleagues reported in Annals of Internal Medicine that among 2563 fully vaccinated patients, the estimated proportion with an undetectable antibody response increased from 6.6 percent at 14-30 days after vaccination to 20.2 percent at 5-6 months. The estimated median index values declined from 91.9 at 14 to 30 days following immunization to 8.4 at 5 to 6 months.

Clinically confirmed COVID-19 emerged in 56 (2%) of the wholly vaccinated individuals after a median follow-up period of 152 days.

Dr. Anand and colleagues suggested that pre-index RBD antibody morals of less than 10 (equivalent to 218 BAU/mL) and value systems from 10 to less than 23 were strongly associated with an 11.6. And 6.0-fold greater likelihood of groundbreaking infection, respectively, when compared to values of 23 or greater (comparable to 506 BAU/mL or higher).

“Our findings imply that five months after vaccination, the majority of vaccinated patients had circulating antibody levels that make them vulnerable to a breakthrough infection,” the scientists stated. “Although the total number of breakthrough infections was low, exposure to SARS-CoV-2 is not uniform, even in the group with low antibody levels, and patients are likely to have tried various mitigation methods, such as masking and social distance.”

Vaccine Antibodies Decline Rapidly In Dialysis Patients
Vaccine Antibodies Decline Rapidly In Dialysis Patients

The researchers noted that the study’s weaknesses included relying on a single measure of vaccination response and determining COVID-19 diagnoses from electronic medical data.

A longer-lasting COVID vaccination has been discovered in a study:

According to the study, vaccines using viral polymerase might help induce a longer-lasting immune response. Researchers have uncovered rare naturally occurring T cells capable of targeting a protein found in SARS-CoV-2 and a range of other coronaviruses. they reported the findings in the scientific journal ‘Cell Reports.’

According to the findings, COVID-19 vaccines might include a viral polymerase component to induce a longer-lasting immune response and boost protection against new virus types.

Most COVID-19 vaccines use a fragment of the spike protein found on the virus’s surface to stimulate the immune system into producing antibodies. Spike protein modifications in newer types, such as delta and omicron, can make them less detectable to immune cells and antibodies generated by immunization.

According to the researchers, a new generation of vaccines will need to build a more solid and broad-based immune response capable of resisting both current and future variants.

One method included a portion of a viral gene protein in immunizations that are less vulnerable to changes than the spike protein and stimulates the defense system’s T cells. Antigens, which are foreign protein fragments, are recognized by molecular receptors on T cells’ surfaces. When a T cell encounters an antigen that its receptor recognizes, it self-replicates and makes additional inflammatory responses, some of which target and destroy sick cells right away. In contrast, others remain in the body for decades to combat the same infection if it resurfaces.

SARS-CoV-2 and other coronaviruses that cause SARS, MERS, and the common cold include the viral polymerase protein, which they studied. Coronaviruses utilize viral polymerases as engines to make copies of them and transmit infection. When viruses evolve, viral polymerases are unlikely to change or mutate.

They next genetically sequenced these receptors using a technology they created called CLInt-Seq. The researchers next designed T cells to contain these polymerase-targeting receptors, allowing them to investigate how well the receptors might detect and kill SARS-CoV-2 and other coronaviruses.

COVID-19 has killed almost 5 million people globally. Current vaccinations offer excellent protection against severe illness. Still, when new, possibly more infectious varieties arise, researchers realize that vaccines could need to be updated — and the latest UCLA findings suggest a technique that might assist boost protection and long-term immunity. The researchers are currently undertaking more studies to see if viral polymerase may be used as a novel vaccine component.

The original study’s first author is Pavlo Nesterenko, a UCLA doctoral candidate; Dr. Owen Witte’s corresponding author. Who retains the presidency chair informative cell biology in the UCLA Department of Microbiology, Immunology, and Cell Biology and is the Broad Regenerative Medicine Center’s founding director emeritus.

Vaccine Antibodies Decline Rapidly In Dialysis Patients
Vaccine Antibodies Decline Rapidly In Dialysis Patients

These Participants Exhibit Super-Antibodies After Getting Covid Shot:

Virologist Linfa Wang from Duke-NUS Medical School has spent a lifetime investigating bat-borne viruses and has developed a universal Covid vaccine. When Covid-19 first appeared in early 2020, Linfa Wang’s first instinct was to test the blood of those who had survived a previous coronavirus outbreak.

The virologist has spent decades at Duke-NUS Medical School, a joint venture between Duke and the National University of Singapore, researching bat-borne viruses. SARS-CoV-1, which killed over 800 people in 2003, was likely transmitted to humans by horseshoe bats, according to his research. Wang’s new idea was that those who had recovered from the initial SARS virus could have antibodies that could help them fight the new SARS-CoV-2 strain.

Initially, the experiment failed miserably. Wang only found antibodies against the earlier type of SARS in the people he examined. He chose to retest the individuals when several Covid variants began circulating earlier this year. Many SARS survivors in Singapore had also had Covid vaccination at the time, giving them a unique set of immune systems that had been exposed to proteins from these related coronaviruses.

Wang was taken aback when he learned what he did. After receiving the Covid injection, the SARS patients produced antibodies similar to super-antibodies, which prevented SARS and several other coronaviruses.

All eight patients had antibodies that neutralized five bat and pangolin coronavirus strains that had never infected humans in test tubes. The findings, which were published in August in the New England Journal of Medicine, offered one of the most important reasons for creating a universal coronavirus vaccine. The demand is increasing. Three new coronavirus illnesses have developed in barely 20 years, as public health professionals are all too aware: first SARS, then MERS in 2012, and now Covid.

Also Read: A Study Demonstrates That Prone Posture Enhances Survival In COVID Patients In Hospitals

Leave a Comment